03 Feb 2012 Southwest Oncology Group Current and Projected Accrual by Committee
Data as of 03 Feb 2012
Therapeutic Registrations by SWOG Institutions Only (Txca=Y)
9% of Calendar Year is Past
Projected 12 Month
2012 Percentage Projected Increase Accrual Increase
Base Accrual Accrual of Base 2012 (Decrease) Last (Decrease)
Committee 2009 to date Accrual Accrual from Base 12 Months from Base
--------- ------------ ---------- ---------- --------- ---------- --------- ----------
BREAST 2292 116 5% 1245 <1047> 959 <1333>
ERLYTX 41 0 0% 0 <41> 4 <37>
GI 421 27 6% 290 <131> 321 <100>
GU 599 60 10% 644 45 396 <203>
GYN 0 0 0 0 57 57
LEUK 192 23 12% 247 55 155 <37>
LUNG 231 33 14% 354 123 435 204
LYMPH 95 17 18% 183 88 111 16
MELAN 97 13 13% 140 43 73 <24>
MMYEL 64 16 25% 172 108 144 80
------------ ---------- --------- ---------- --------- ----------
4032 305 3274 <758> 2655 <1377>
03 Feb 2012 Southwest Oncology Group Current and Projected Accrual by Committee
Data as of 03 Feb 2012
Non-Therapeutic Registrations by SWOG Institutions Only
9% of Calendar Year is Past
Projected 12 Month
2012 Percentage Projected Increase Accrual Increase
Base Accrual Accrual of Base 2012 (Decrease) Last (Decrease)
Committee 2009 to date Accrual Accrual from Base 12 Months from Base
--------- ------------ ---------- ---------- --------- ---------- --------- ----------
BREAST 10 0 0% 0 <10> 1 <9>
GI 0 0 0 0 4 4
GU 0 2 21 21 9 9
LEUK 318 0 0% 0 <318> 53 <265>
LUNG 78 0 0% 0 <78> 7 <71>
LYMPH 42 0 0% 0 <42> 4 <38>
MMYEL 75 0 0% 0 <75> 16 <59>
PREV 0 1 11 11 4 4
SXQOL 33 0 0% 0 <33> 0 <33>
------------ ---------- --------- ---------- --------- ----------
556 3 32 <524> 98 <458>
03 Feb 2012 Southwest Oncology Group Current and Projected Accrual by Committee
Data as of 03 Feb 2012
All Initial Registrations by SWOG Institutions
9% of Calendar Year is Past
Projected 12 Month
2012 Percentage Projected Increase Accrual Increase
Base Accrual Accrual of Base 2012 (Decrease) Last (Decrease)
Committee 2009 to date Accrual Accrual from Base 12 Months from Base
--------- ------------ ---------- ---------- --------- ---------- --------- ----------
BREAST 2302 116 5% 1245 <1057> 960 <1342>
ERLYTX 41 0 0% 0 <41> 4 <37>
GI 421 27 6% 290 <131> 325 <96>
GU 599 62 10% 666 67 405 <194>
GYN 0 0 0 0 57 57
LEUK 510 23 5% 247 <263> 208 <302>
LUNG 309 33 11% 354 45 442 133
LYMPH 137 17 12% 183 46 115 <22>
MELAN 97 13 13% 140 43 73 <24>
MMYEL 139 16 12% 172 33 160 21
PREV 0 1 11 11 4 4
SXQOL 33 0 0% 0 <33> 0 <33>
------------ ---------- --------- ---------- --------- ----------
4588 308 3306 <1282> 2753 <1835>
03 Feb 2012 Southwest Oncology Group Current and Projected Accrual by Committee
Data as of 03 Feb 2012
Initial Registrations to Cancer Control Studies
9% of Calendar Year is Past
Projected 12 Month
2012 Percentage Projected Increase Accrual Increase
Base Accrual Accrual of Base 2012 (Decrease) Last (Decrease)
Committee 2009 to date Accrual Accrual from Base 12 Months from Base
--------- ------------ ---------- ---------- --------- ---------- --------- ----------
BREAST 188 95 51% 1020 832 516 328
GI 0 1 11 11 4 4
GU 496 0 0% 0 <496> 0 <496>
LUNG 88 0 0% 0 <88> 14 <74>
LYMPH 4 0 0% 0 <4> 0 <4>
PREV 0 1 11 11 4 4
SXQOL 33 0 0% 0 <33> 0 <33>
------------ ---------- --------- ---------- --------- ----------
809 97 1041 232 538 <271>
03 FEB 2012 Southwest Oncology Group Open and Temporarily Closed Studies
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.
Monthly Date of
Stat Open Months Total Accrual Accrual Expected Closure or
Comm. Phase Study Center Date Open Regs Goal Rate Temporary Closure
------ ------ -------------------------------------- -------- ---------- ------ ------ ------- ------- --------------------
BREAST II Z1071 Node+, chemo + LN dissect ACOSOG 22-JUL-09 67 .0
S0800 Brst,Neoadj nabPAC+/-Bev->AC+G SWOG 01-APR-10 22 123 200 9.0 Oct-2012
C40603 Carb/Bev+Neoadj Pac, then AC/EC CALGB 21-MAY-10 35 1.5
E3108 CYP2D6 Activity&SingleAgTamox ECOG 08-OCT-10 5 .8
III C40101 Breast, Adj, Node neg, AC vs T CALGB 15-MAY-02 733 .0
JMA20 Breast, Early, Regional RT NCIC 03-OCT-02 8 .0
IBC24-02 Ovar Ftn suppress/premeno IBCSG 04-AUG-03 187 .0
B39 Stg 0-2, whole vs partial RT NSABP 22-MAR-05 14 .0
C70301 QOLEmployInformCareCost Analysi CALGB 24-OCT-05 35 .0
s
N0434 JMA27 Companion Study NCCTG 08-DEC-05 100 .0
JMA27B 5yr Adj Anast vs Exemestrane NCIC 24-APR-06 94 .0
PACCT-1 Assess of Ca Clinical Tests ECOG 24-APR-06 1712 .0
C40302 Endocrine +/1 Inhibition CALGB 22-SEP-06 28 .0
S0500 Brst,Adv,CTC,mntain v chnge tx SWOG 01-OCT-06 64 604 500 10.7 May-2011
E1105 Adv, Trastuzumab +/- Bev ECOG 21-NOV-07 15 .0
N063D ALTTO NCCTG 15-FEB-08 119 .0
C40503 EndocrineTxCombo w/AntiVEGF Tx CALGB 22-MAY-08 39 .7
N0733 Her2+, Cap + Lap +/- IMC-A12 NCCTG 30-JUL-08 5 .3
C40601 NeoAdj, Her-2+, Pac+Trast or La CALGB 08-DEC-08 30 2.3
p
MA32 Metformn vs Placebo NCIC 08-JUL-10 250 37.2
B47 Chemo vs Chemo + Trastuzumab NSABP 07-JAN-11 15 1.5
S1007 Breast,Adj,N1,Endocrine+/-Chemo SWOG 15-JAN-11 12 252 4000 35.5 Nov-2020
E2108 Early Local Tx for Int Prim Tum ECOG 28-FEB-11 3 .3
ERLYTX I S0711 Liver dysfunction PK,Dasatinib SWOG 15-OCT-08 54 48 Jan-2012 Temp Close
GI II S0809 EHCC,Adj,Cape+Gem==>Cape+RT SWOG 01-DEC-08 38 99 88 3.8 Dec-2011
S0713 Rect,Stg2-3,Ox/Cape/Cet+RT->SRG SWOG 01-FEB-09 36 55 88 2.0 Jun-2013
S1005 Gastric/GEJ, Adv, MK-2206 SWOG 01-JAN-11 13 25 64 2.7 Apr-2013
III C80405 GI,Met,FOLFOX/FIRI,Bev,Cetux CALGB 26-SEP-05 640 2289 5.7
S0518 CARCINOID,ADV,OCTREO/ALPHA/BEV SWOG 01-DEC-07 50 375 424 7.0 Aug-2012
E1208 Chemo Soraf. in Unresect HCC ECOG 09-NOV-09 16 1.8
R0848 Panc, Adj, Erlotinib v ChemoRT RTOG 08-DEC-09 6 .5
C80802 Soraf+Doxorubicin vs Sorafenib CALGB 22-FEB-10 3 .3
C80702 Adj FOLFOX+Celecoxib or Placebo CALGB 22-JUN-10 113 7.7
R1010 Trastuz + Tri Tx of HER2-Overex RTOG 07-JAN-11 1 .2
GU II S0925 Andro Dep w/IMC vs. Andro Dep SWOG 15-DEC-10 13 89 198 9.7 Jan-2013
S1014 Pros, Mets, Abi Acetate SWOG 09-AUG-11 5 0 38 .0 > 15 Yrs
III MDA3410 Consolidation chemo MDACC 08-MAY-02 22 .0
C90202 Pros,Bone mets,Zoledronic acid CALGB 15-JAN-04 77 .5
R0521 AS+RT vs AS+RT+Chemo RTOG 22-DEC-05 18 .0
R0415 Hypofrac v Conv 3D-CRG/IMRT RTOG 24-APR-06 1 .0
E2805 Renal, Adj Sunitib v Sorafinib ECOG 08-MAY-06 583 .0
E3805 CHAARTED ECOG 08-AUG-06 125 3.0
R0524 Pac + Trastuzumab vs Pac alone RTOG 08-DEC-06 5 .0
C90203 Pros, Surgery +/- Neoadj Chemo CALGB 22-DEC-06 83 1.2
S0337 Blad, Instill Gem vs Saline SWOG 15-JUL-07 54 312 408 14.2 Aug-2012
PR11 Pros, Local, Watch vs Active Tx NCIC 15-JUL-07 8 .0
E2804 BeST Trial ECOG 21-MAR-08 44 .0
C90601 Trans cell, blind bev vs placeb CALGB 07-AUG-09 39 2.0
o
C70807 MEAL Study CALGB 21-JAN-11 9 1.5
S0931 EVEREST SWOG 01-APR-11 10 104 1218 16.2 Oct-2017
S1011 Blad, Standard vs Extended LND SWOG 01-AUG-11 6 11 620 1.8 > 15 Yrs
LEUK II S0535 APL,High Risk, ATRA/arsenic/GO SWOG 15-NOV-07 50 54 77 2.0 Jan-2013
C10403 ALL <40 yrs-Ped,Chemo. Regimen CALGB 15-JAN-08 48 65 300 2.2
S0703 AML, age 60+, Azacitidine G.O. SWOG 01-DEC-08 38 132 153 4.3 Jun-2012
C10404 CLL, Flu/Rituxan combinations CALGB 15-MAR-09 34 26 300 1.0
S0919 Rel AML: Pravastatin+Ida+Ara-C SWOG 15-AUG-09 29 25 55 1.3 Dec-2013
S0805 Ph+ ALL, Dasatinib/CVAD +/- BMT SWOG 01-SEP-09 29 23 94 2.0 Jan-2015
S0910 Rel ph-,B-ALL,Epratuzumab+Cy+Clo SWOG 15-AUG-10 17 25 35 2.2 Jun-2012
E1908 Tx of PCL Leuk w/Alemtuz, Ritux ECOG 22-OCT-10 1 .2
III E2905 MDS, Len vs Len + Epo ECOG 09-FEB-09 21 .7
LUNG I-II S0905 Mesothem,cediranib+chemo,PhI/II SWOG 15-MAR-10 22 25 128 .8 May-2022
II S0720 NSCLC,STG I,ERCC1/RRM1 TO ADJ TX SWOG 15-NOV-08 85 60 Apr-2011 Temp Close
S0709 NSCLC, Adv, PRO+, OSI-774+-Chemo SWOG 01-DEC-08 38 37 110 1.5 Feb-2016
S0802 ESCLC,Topotecan+/-AVE0005,PhII SWOG 15-MAY-09 32 188 190 4.5 Feb-2012
III E1505 Stg IB-IIIA chemo +/- Bev ECOG 22-JUN-07 216 4.0
C140503 NSCL, Lobect v Sublobar resect CALGB 09-JUL-07 13 .2
C30610 SCLC, Thoracic RT CALGB 21-MAR-08 29 .7
S0819 NSCLC, ADV, CHEMO/BEV +/-CET SWOG 15-JUL-09 30 643 1700 26.7 May-2015
C30801 Selective COX-2 Inhibition CALGB 22-JUL-10 5 .2
N107C SRS vs WBRT on Resected Met Dz NCCTG 08-JUL-11 0 .0
LYMPH I-II S0806 NHL, Adv, R-CHOP + SAHA SWOG 15-NOV-10 14 25 105 2.8 Jun-2014
II S0816 HD, Adv, PET-Adapted Therapy SWOG 01-JUL-09 31 235 200 11.8 Dec-2011
C50604 Resp-Adapt Chemo Pos Emiss Tomo CALGB 22-JUL-10 15 1.3
S1001 DLBCL, I-II, PET-Adapted Therapy SWOG 15-JUL-11 6 3 155 .5 > 15 Yrs
S1106 NHL, Adv, R-HCVAD/R-Benda+PBSCT SWOG 01-OCT-11 4 3 180 .7 > 15 Yrs
S1108 NHL, Relapsed PTCL, MLN8237 SWOG 28-OCT-11 3 2 39 .6 Jan-2017
III C50303 R-CHOP v EPOCH-R CALGB 15-SEP-06 43 .7
CTN0701 Relapsed follic, allo transpla BMT-CTN 23-FEB-09 3 .0
nt
MELAN II E2607 Dasatinib in KIT+ pts w/Melanoma ECOG 22-NOV-11 0
III E1609 Adj Ipil AntiCTLA4 vs Interferon ECOG 08-JUN-11 41 6.8
MMYEL II S0833 Frontline MM, Total Therapy III SWOG 15-MAR-11 10 0 100 .0 > 15 Yrs
III S0777 MM, Len Dex +/- Bortezomib SWOG 01-APR-08 46 525 484 15.7 Dec-2011
CTN0702 Single v Tandem Autol transpla BMT-CTN 09-JUN-10 12 .8
nt
E3A06 Lenalidomide vs Observation ECOG 08-NOV-10 7 .3
E4A08 MDex vs BMDex in untx pts w/AL ECOG 22-NOV-10 0 .0
PREV II S0812 Breast, Prev, Vit D vs Placebo SWOG 01-NOV-11 3 4 220 1.3 Dec-2025
SXQOL III S0927 Omega-3-Fatty Acid AI Joint Pain SWOG 01-FEB-12 0 0 246
SWOG StatCtr Home Page